Novo Nordisk released its Q3 results today with a mixed set of numbers for the quarter but yet another downgrade was the biggest disappointment. It has further revised down its long-term operating profit growth guidance from 10% to 5%, following the first downgrade at the beginning of this year from 15% (set in 1996) to 10%. While the revision from 15% to 10% was a practical acknowledgment of the market’s realities and hence was not perturbing for us, today’s revision is worrying.
28 Oct 2016
Another downgrade triggers panic; our first take on the results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Another downgrade triggers panic; our first take on the results
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
28 Oct 2016 -
Author:
Kamla Singh -
Pages:
2
Novo Nordisk released its Q3 results today with a mixed set of numbers for the quarter but yet another downgrade was the biggest disappointment. It has further revised down its long-term operating profit growth guidance from 10% to 5%, following the first downgrade at the beginning of this year from 15% (set in 1996) to 10%. While the revision from 15% to 10% was a practical acknowledgment of the market’s realities and hence was not perturbing for us, today’s revision is worrying.